Compare ALHC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALHC | ACAD |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.8B |
| IPO Year | 2021 | 2000 |
| Metric | ALHC | ACAD |
|---|---|---|
| Price | $21.76 | $22.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | $23.13 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 3.3M | 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | ★ $3,948,719,000.00 | $726,437,000.00 |
| Revenue This Year | $33.69 | $18.80 |
| Revenue Next Year | $24.74 | $11.70 |
| P/E Ratio | $405.00 | ★ $9.64 |
| Revenue Growth | ★ 46.06 | 40.45 |
| 52 Week Low | $11.63 | $14.45 |
| 52 Week High | $23.87 | $28.35 |
| Indicator | ALHC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 52.81 |
| Support Level | $19.93 | $20.80 |
| Resistance Level | $22.87 | $22.97 |
| Average True Range (ATR) | 0.70 | 0.60 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 68.56 | 77.87 |
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.